Source: Targeted Oncology, June 2025
Theresa Medina, MD, associate professor of medicine-medical oncology at the University of Colorado Cancer Center, Anschutz Medical Campus, discusses the C-144-01 study (NCT02360579) of lifileucel (Amtagvi) in patients with advanced melanoma and data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
In the phase 2, registrational, open-label, multicenter, multicohort, C-144-01 trial, patients treated with lifileucel had an objective response rate (ORR) of 31.4%, as assessed by an independent review committee. These findings come from a 5-year follow-up of the C-144-01 trial that assessed the long-term efficacy and safety of lifileucel.